Drugs / B1
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 33 trials | ||||||
| Phase 3 | NCT05619328 | Sep 2022 → Nov 2023 | sensory peripheral neuropathy | Procter and Gamble | Completed | No outcome recorded |
| Phase 3 | NCT01295450 | Apr → Aug 2011 | eating disorder | MDCPharma Produtos Farmaceuticos LTDA | Unknown | No outcome recorded |
| Phase 3 | NCT00170404 | Jun 2000 → Oct 2005 | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06446830 | May 2024 → Nov 2025 overdue | — | Ain Shams University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05619328 ↗ |
| Route | Oral | “receive either oral vitamin B combination daily or matching placebo” NCT05619328 ↗ |